

## Technology Appraisal Committee D Interests Register

**Topic: Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]**

**Publication Date: 12 February 2025**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Bernard Khoo	TAC Committee Member	Indirect	Bernard's wife is working with Eli Lilly on an unrelated project concerning diabetes.	29/04/2024	It was agreed that Bernard's declaration would not prevent them from participating in discussions on this appraisal.
Will Sullivan	TAC Committee Member	Financial	In Will's role as a consultant, his employer is paid for him to provide consultancy services to various pharmaceutical companies. In the last 12 months, this has not included Eli Lilly. Will has no prior professional experience of selpercatinib.	01/05/2024	It was agreed that Will's declaration would not prevent them from participating in discussions on this appraisal.